RDEA3170 + Febuxostat + Benzbromarone
Phase 1/2Completed 2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gout and Asymptomatic Hyperuricemia
Conditions
Gout and Asymptomatic Hyperuricemia
Trial Timeline
Dec 1, 2014 → Jun 1, 2015
NCT ID
NCT02317861About RDEA3170 + Febuxostat + Benzbromarone
RDEA3170 + Febuxostat + Benzbromarone is a phase 1/2 stage product being developed by AstraZeneca for Gout and Asymptomatic Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02317861. Target conditions include Gout and Asymptomatic Hyperuricemia.
What happened to similar drugs?
7 of 20 similar drugs in Gout and Asymptomatic Hyperuricemia were approved
Approved (7) Terminated (3) Active (11)
🔄SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02317861 | Phase 1/2 | Completed |
Competing Products
20 competing products in Gout and Asymptomatic Hyperuricemia